Termination of Mr Daniel Kenny as Chief Executive Officer
Filed with ASX · · 2 pages · English
Sydney, Australia – 2 December 2020: The Board of OncoSil Medical Ltd (ASX: OSL) (OncoSil or the Company) announces that its Chief Executive Officer, Mr. Daniel Kenny, has been terminated effective today. The Board would like to thank Daniel for his services and contribution to OncoSil over the last 6 years. As the Board undertakes a process for Daniel Kenny’s replacement, OncoSil’s current Chairm
Earlier from OncoSil Medical
- OncoSil receives Swiss regulatory approval
- OncoSil achieves first commercial sale
- Positive PanCO trial update on resected cohort
- Receipt of $2.8m R&D Tax Incentive Refund
- Investor Update
Later from OncoSil Medical
- OncoSil FY21 half yearly review
- Appointment of Chief Executive Officer
- Appendix 4C - quarterly
- OncoSil receives regulatory approval from Hong Kong
- OncoSil TGA regulatory update
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical